In order to reduce the adverse effects of anticancer drugs, the new dosage form comprised activated carbon particles (Mitsubisi#1500AAR, specially prepared by Mitsubisi Chemical Industries Co., Ltd, Tokyo, Japan) adsorbing aclarubicin was devised. The new dosage form composed of aclarubicin and activated carbon particles ten times as weighty as aclarubicin in saline. The acute toxicity of the new dosage form(ACR-CH) injected intraperitoneally was studied in mice. The LD50 value of ACR-CH was over 75mg/kg in terms of aclarubicin, otherwise that of aclaruhicin aqueous solusion (ACR-sol) was 32.9mg/kg by means of Litchfield-Wilcoxon's method. Pathological examinations of the animal' organs and examinations about body weight change and symptom of toxicity revealed no remarkable difference between ACR-CH and ACR-sol. Those results show no evidence of any addisional side effects of aclarubicin by the change of dosage form. We concluded that acute toxicity of aclarubicin was reduced by the use of activated carbon particles as a carrier.
